ARCH Venture Partners — Full Portfolio
232 tracked investments · page 2 of 2 · listed companies and verified rows first
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Co-investorsAtlas VentureForesite CapitalThe Column GroupAlexandriaDecheng Capital
Kissht is a technology-enabled digital lender in India offering personal loans up to ₹5 lakh and loans against property up to ₹30 lakh through its mobile application.
AI & Machine LearningFintechInsurTechMumbai, IN
Ranvir Singh(Chairman and Chief Executive Officer, Founder and Promoter)inKrishnan Vishwanathan(Founder and Promoter)
Co-investorsTrifecta Capital AdvisorsSnowflake Ventures
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzGV (Google Ventures)Luma GroupSanofi VenturesAbingworthAdvent Life Sciences+11 more
Supernus is a biopharmaceutical company focused on developing and commercializing products that treat central nervous system (CNS) diseases.
BiotechHealthtech
Co-investorsEcoR1 Capital
Scale Biosciences develops patented single-cell analysis technology that enables researchers to conduct massively parallelized sequencing at reduced cost.
AI & Machine LearningBiotechDeep Tech
Garry Nolan(Scientific Co-Founder)Frank Steemers(Scientific Co-Founder)inJay Shendure(Scientific Co-Founder)Cole Trapnell(Scientific Co-Founder)in
SciNeuro develops targeted therapeutics for neurodegenerative and age-related brain diseases by integrating patient genetics, health history, and advanced diagnostic tools.
BiotechDeep TechDigital HealthLongevityMedical DevicesRockville, US
Min Li(CEO & Director)inSam Agus(CSO/CMO)Paul Stead(CBO)in
Co-investorsGeneral AtlanticLAV
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology Fund6 Dimensions CapitalCowen Healthcare Investments+4 more
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
Nan Fang(PhD, MBA; CEO and Founder)inJing Zhou(PhD; CSO (co-founder))inRong Fan(Co-Founder of Singleron, Professor Yale University)in
Co-investorsLAVLilly Asia VenturesLake Bleu CapitalMSA CapitalSBCVCSherpa Healthcare Partners+1 more
Singular Genomics develops spatial pathology technology to map molecules and cells directly in tissue for disease characterization.
BiotechDeep TechMedical DevicesSan Diego, US
John Stark(CEO)Aaron Berlin(CTO)in
Co-investorsCatalio Capital Management, LPCoatue ManagementF-Prime Capital
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.
BiotechHealthtechLongevityWaltham, US
Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)
Co-investorsF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture InnovationGaorong Capital+6 more
Sonoma provides a governance platform for enterprise deployments of AI agents built on the Model Context Protocol (MCP), offering a self-service MCP catalog, workflow builder, entitlement policies, audit logging, and security controls such as supply chain scanning and prompt injection protection.
AI & Machine LearningCybersecurityEnterprise Software
Stephen Cobbe(Founder)in
Co-investorsFrazier Life SciencesGoAhead VenturesHawk Hill Ventures8VCAlexandriaLifeforce Capital
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAVLifeforce Capital+6 more
Biotechnology company developing blood-based diagnostic tests for neurological disorders and early-stage cancer.
Cambridge, US
Co-investorsAlumni VenturesClavystBioPolaris PartnersS32
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Founder)inThomas Oxley(Founder)inTom Oxley(Founder)
BoardRahul Sharma(Director)Alex Morgan(Director)in
Co-investorsAlumni VenturesForepont Capital PartnersID8 InvestmentsIn-Q-TelK2 GlobalKaleida Capital+15 more
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Smith(Founder & CEO)inJason Betley(Chief Product Officer)in
Co-investors+ND CapitalOMX Ventures
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Anthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)
Co-investorsBayMed Venture PartnersCross Creek AdvisorsEric F. ThiessenExcel Venture ManagementHeran PartnersHighsage Ventures+6 more
Hong Kong-listed, Suzhou-headquartered biopharmaceutical company developing antibody therapeutics with in-house biomanufacturing.
Suzhou, CN
Xueming Qian(Executive Director, Chairman and CEO)in
Co-investorsChina Structural Reform FundFortune Venture CapitalHillhouse CapitalLilly Asia VenturesQatar Investment AuthorityTemasek
Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.
AI & Machine LearningBiotechDeep Tech
Co-investorsBlueYard CapitalGaingelsJAZZ Venture PartnersDCVC BioInsight PartnersMayo Clinic Ventures
Trase builds AI systems with built-in governance and auditability for organizations in high-stakes domains such as defense, healthcare, and critical infrastructure.
AI & Machine LearningDeep TechDefense TechEnterprise SoftwareHealthtech
Joe Laws(Co-Founder and Chief Architect)inGrant Verstandig(Co-Founder and CEO)in
Co-investorsRed Cell Incubation
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsLightstone VenturesMedical Excellence CapitalCanaan Partners
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investors5AM VenturesClarus VenturesK2 HealthVentures
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersWellington ManagementCasdin Capital+3 more
Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates.
AI & Machine LearningBiotechDeep TechCambridge, US
Yasir Al-Wakeel(CEO)inYasir Al-Wakeel, BM BCh(Chief Executive Officer)Doug Cole, MD(Managing Partner, Flagship Pioneering; Founder Vesalius)
Co-investorsFlagship PioneeringSofinnova Ventures
Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature.
AI & Machine LearningBiotechDeep Tech
David Baker(Founder)Patrick Salveson, PhD(Co-Founder, CTO)Adam Moyer, PhD(Co-Founder, VP of Molecular Design)David Baker, PhD(Nobel laureate, Co-Founder, Director, IPD UW, Prof. Biochemistry)Gaurav Bhardwaj, PhD(Co-Founder, UW, Asst. Prof. Medicinal Chemistry)Lance Stewart, PhD, MBA(Co-Founder, CSO & COO, IPD)
Co-investorsMadrona Venture GroupMenlo VenturesNVIDIAAltitude Ventures Management, LlcAlumni VenturesAtomic+10 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsDroia VenturesB Capital GroupB4 CapitalVida VenturesCatalio Capital ManagementPolaris Partners
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical DevicesCambridge, US
Blaine McKee, Ph.D.(Chief Executive Officer)
Co-investorsATEM Capital FundPandect BioventuresUCB Ventures
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Founder)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)Bob Nelsen(Founder)
Co-investorsBreyer CapitalDeviation CapitalF-Prime CapitalForesite CapitalForesite LabsLongwood Fund+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Sage TherapeuticsSciNeuroSorbent TherapeuticsTome BiosciencesUltraDx Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.










































































__Twitter.png)





































.jpeg)




